Evidence map›Paper›PMID 41328860›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2026

Remote-Controllable Immune-Priming Spot Formation Via Nanocomplexed Hydrogel-Assisted Histotripsy: Immunoasis.

Sung Hoon Kim, Wonseok Choi, Yurim Kim, Hyeongmin Kim, Gu Won Jeong, Hyewon Park, Inchan Youn, Yoon Park, Sungmin Han, Young-Min Kim

Abstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sung Hoon KimBiomaterials Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Wonseok ChoiBionics Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Yurim KimBiomaterials Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Hyeongmin KimBionics Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Gu Won JeongBiomaterials Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Hyewon ParkBionics Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Inchan YounBionics Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Yoon ParkChemical and Biological Integrative Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Sungmin HanBionics Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.
Young-Min KimBiomaterials Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-0912-3010

Funding

Korea Institute of Science and Technology 2E33151Korea Institute of Science and Technology 2E33771Korean National Police Agency RS-2022-PT000188Ministry of Education RS-2025-25422961Ministry of Science and ICT, South Korea RS-2021-NR061536Ministry of Science and ICT, South Korea RS-2023-00244748Ministry of Science and ICT, South Korea RS-2024-00403376Ministry of Science and ICT, South Korea RS-2025-02073096Ministry of Science and ICT, South Korea RS-2025-02223083Ministry of Trade, Industry and Energy 20014477
6 · The paper itself

Abstract

Immunotherapy, which harnesses the immune system to eliminate cancer cells, offers durable, and specific responses. However, many tumors exhibit "immune deserts" - immunosuppressive microenvironments with low T cell infiltration due to the dominance of suppressive myeloid cells and limited inflammatory cues. Cancer vaccines combining tumor antigens and adjuvants can potentially convert these immune deserts into immune-active lesions. Yet, systemic administration often leads to adverse effects such as cytokine storms and off-target immune activation. To address this, we propose "Immunoasis", a spatiotemporally controllable immunotherapeutic system. This platform integrates injectable, adjuvant-loaded hydrogels with externally triggered boiling histotripsy. The hydrogel enables prolonged local retention of immunostimulatory payloads, while histotripsy disrupts tumor tissues and induces in situ conversion of the gel into nanocomplexes enriched with antigens and adjuvants. This localized activation enhances antigen presentation and promotes T cell recruitment at the tumor site. The tunable nature of the ultrasound stimulus provides flexible treatment scheduling and supports personalized cancer therapy. By establishing immune-priming niches within the tumor, Immunoasis effectively transforms immune deserts into immune-responsive microenvironments, enhancing antitumor immunity and improving therapeutic efficacy.

Indexed as

HydrogelsAdjuvants, ImmunologicAnimalsCell Line, TumorHumansImmunotherapyMiceNeoplasmsT-LymphocytesTumor MicroenvironmentAdjuvants, ImmunologicHydrogelsinjectable hydrogelin situ cancer vaccinemulti‐targetablenanocomplexespatient‐favorable

Identifiers

PMID41328860
PMCPMC13088224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.